134 related articles for article (PubMed ID: 9118747)
1. Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model.
Akhter J; Chen X; Bowrey P; Bolton EJ; Morris DL
Dis Colon Rectum; 1997 Mar; 40(3):317-21. PubMed ID: 9118747
[TBL] [Abstract][Full Text] [Related]
2. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089.
VanWeelden K; Flanagan L; Binderup L; Tenniswood M; Welsh J
Endocrinology; 1998 Apr; 139(4):2102-10. PubMed ID: 9528999
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study.
Ghous Z; Akhter J; Pourgholami MH; Morris DL
Anticancer Res; 2008; 28(6A):3757-61. PubMed ID: 19189661
[TBL] [Abstract][Full Text] [Related]
4. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089.
Zhang X; Jiang F; Li P; Li C; Ma Q; Nicosia SV; Bai W
Clin Cancer Res; 2005 Jan; 11(1):323-8. PubMed ID: 15671562
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
Lokeshwar BL; Schwartz GG; Selzer MG; Burnstein KL; Zhuang SH; Block NL; Binderup L
Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):241-8. PubMed ID: 10090302
[TBL] [Abstract][Full Text] [Related]
6. Antineoplastic effect and toxicity of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 in athymic mice with Y-79 human retinoblastoma tumors.
Sabet SJ; Darjatmoko SR; Lindstrom MJ; Albert DM
Arch Ophthalmol; 1999 Mar; 117(3):365-70. PubMed ID: 10088815
[TBL] [Abstract][Full Text] [Related]
7. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer.
El Abdaimi K; Papavasiliou V; Rabbani SA; Rhim JS; Goltzman D; Kremer R
Cancer Res; 1999 Jul; 59(14):3325-8. PubMed ID: 10416587
[TBL] [Abstract][Full Text] [Related]
8. Effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and its analogues (EB1089 and analog V) on canine adenocarcinoma (CAC-8) in nude mice.
Kunakornsawat S; Rosol TJ; Capen CC; Reddy GS; Binderup L; Inpanbutr N
Biol Pharm Bull; 2002 May; 25(5):642-7. PubMed ID: 12033506
[TBL] [Abstract][Full Text] [Related]
9. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.
Haq M; Kremer R; Goltzman D; Rabbani SA
J Clin Invest; 1993 Jun; 91(6):2416-22. PubMed ID: 8514854
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy.
Díaz GD; Paraskeva C; Thomas MG; Binderup L; Hague A
Cancer Res; 2000 Apr; 60(8):2304-12. PubMed ID: 10786699
[TBL] [Abstract][Full Text] [Related]
11. EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer.
Milliken EL; Zhang X; Flask C; Duerk JL; MacDonald PN; Keri RA
Cancer Lett; 2005 Nov; 229(2):205-15. PubMed ID: 16115727
[TBL] [Abstract][Full Text] [Related]
12. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice.
Blutt SE; Polek TC; Stewart LV; Kattan MW; Weigel NL
Cancer Res; 2000 Feb; 60(4):779-82. PubMed ID: 10706079
[TBL] [Abstract][Full Text] [Related]
13. EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro.
James SY; Mercer E; Brady M; Binderup L; Colston KW
Br J Pharmacol; 1998 Nov; 125(5):953-62. PubMed ID: 9846632
[TBL] [Abstract][Full Text] [Related]
14. Action of low calcemic 1alpha,25-dihydroxyvitamin D3 analogue EB1089 in head and neck squamous cell carcinoma.
Prudencio J; Akutsu N; Benlimame N; Wang T; Bastien Y; Lin R; Black MJ; Alaoui-Jamali MA; White JH
J Natl Cancer Inst; 2001 May; 93(10):745-53. PubMed ID: 11353784
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D receptor-dependent inhibition of mammary tumor growth by EB1089 and ultraviolet radiation in vivo.
Valrance ME; Brunet AH; Welsh J
Endocrinology; 2007 Oct; 148(10):4887-94. PubMed ID: 17628009
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion.
Flanagan L; Packman K; Juba B; O'Neill S; Tenniswood M; Welsh J
J Steroid Biochem Mol Biol; 2003 Feb; 84(2-3):181-92. PubMed ID: 12711002
[TBL] [Abstract][Full Text] [Related]
17. [Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model].
Lu J; Jin J; Xu WL
Zhonghua Er Ke Za Zhi; 2006 Mar; 44(3):228-33. PubMed ID: 16624066
[TBL] [Abstract][Full Text] [Related]
18. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells.
James SY; Mackay AG; Binderup L; Colston KW
J Endocrinol; 1994 Jun; 141(3):555-63. PubMed ID: 8071654
[TBL] [Abstract][Full Text] [Related]
19. Anticancer effects of the novel 1alpha, 25-dihydroxyvitamin D3 hybrid analog QW1624F2-2 in human neuroblastoma.
Reddy CD; Patti R; Guttapalli A; Maris JM; Yanamandra N; Rachamallu A; Sutton LN; Phillips PC; Posner GH
J Cell Biochem; 2006 Jan; 97(1):198-206. PubMed ID: 16200638
[TBL] [Abstract][Full Text] [Related]
20. Effect of a vitamin D3 analog, EB1089, on hematopoietic stem cells from normal and myeloid leukemic blasts.
Lee YY; Kim ES; Seol JG; Kim BK; Binderup L; Elstner E; Park DJ; Koeffler HP
Leukemia; 1996 Nov; 10(11):1751-7. PubMed ID: 8892678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
